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Abstract
HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and
occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted
drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities
across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by
the World Health Organization’s 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM preva-
lence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine
analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor
(NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into
three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N,
K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and
M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%)
patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in
3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and
TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V,
V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of
HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and
treatment efforts.
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Introduction
Today, treatment of HIV-1 infection is based on acombination of three or more targeted drugs and is
referred to as highly active antiretroviral therapy (HAART).
A combination of two nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTIs) and a third agent, which may be
selected from nonnucleoside reverse transcriptase inhibitors
(NNRTIs), one of several ritonavir-boosted protease inhibi-
tors (PIs), or the new class of integrase strand transfer
inhibitors (INSTIs), is currently recommended for first-line
therapy.1
A major cause of antiretroviral resistance mutations in
newly diagnosed HIV-1-infected patient is transmission of this
strain from another HIV-1-infected individual.2 The turnover
of the HIV-1 population is rapid (approximately 1 day) and
error-prone (mutation rate ca. 3 · 10-5 mutations/base/repli-
cation cycle), resulting in a large and genetically diverse
population in vivo in which resistance may emerge.3 Analysis
of the kinetics of emergence of drug resistance in vivo suggests
that many single nucleotide mutations conferring drug resis-
tance may be present prior to the start of HAART.4 In 2004, the
European HIV Drug Resistance Guidelines Panel presented
recommendations for the use of initial HIV-1 drug resistance
testing managing treatment for HIV-1 infection.5 However, all
current guidelines recommend HIV-1 drug resistance testing
for all HIV-1-infected patients prior to therapy initiation.1,6,7
The World Health Organization (WHO) is conducting a
global surveillance of transmitted HIV-1 drug resistance.
Transmitted HIV-1 drug resistance is classified into three
categories according to this surveillance: low prevalence
(<5%), moderate prevalence (5–15%), and high prevalence
(>15%).8 In a population, genotypic resistance testing is
considered cost effective for HIV-1 infection when the level
of transmitted drug resistance is >5%.9
According to the official HIV/AIDS annual surveillance
data of the Turkey Ministry of Health, 1,767 patients were
newly diagnosed with HIV-1 in 2014. In the period between
1985 and 2014 there were only 9,379 cumulative HIV/AIDS
cases in Turkey, and so by the end of 2014, the cumulative
increase in HIV-1 patients was 38%.10 According to the IMS
Health Turkey there are 4,117 HIV-1-infected patients under
antiretroviral therapy (ART).11 However, there is limited
knowledge of transmitted drug resistance mutations (TDRMs)
of HIV-1 strains in Turkish patients. In a single study with 117
newly diagnosed HIV-1-infected Turkish cases, the preva-
lence of TDRMs was 7.6%.12
The objective of this study is to accurately determine and
to understand the circulation of TDRMs of HIV-1 in newly
diagnosed, untreated patients from a cohort consisting of
individuals from cities in all regions of Turkey.
Materials and Methods
Patient population
The present study was conducted between March 2010 and
March 2015, and it included 1,306 HIV-1-infected patients
who were newly diagnosed in infectious disease departments
of 21 cities from all regions of Turkey. The clinic and labo-
ratory characteristics of the patients are shown in Table 1.
The study was approved by the local ethics committee
(Clinical Research Ethics Committee of Kocaeli University),
and written informed consent was obtained from each patient.
All of the patients were categorized as HIV carriers according
to European AIDS Clinical Society (EACS) Guidelines.1
Based on records of the Turkey Ministry of Health, the study
patients were newly diagnosed and were ART-naive. The
U.S. Centers for Disease Control and Prevention (CDC)
classification system was used to determine the HIV infection
staging of patients.13
Blood samples with K2EDTA were separated by centri-
fugation immediately, aliquoted, and then kept at -80C until
testing. Anti-HIV-1/2 antibody was tested using commer-
cially available microparticle enzyme immunoassay kits
(Axsym; Abbott Laboratories, Abbott Park, IL, and Elecsys,
Roche Diagnostics, Mannheim, Germany). All of the samples
that were anti-HIV positive by ELISA at least two times were
confirmed by a Western blot test (DIA PRO, HIV-1 LIA,
Diagnostic Bioprobes Srl, Milano, Italy) in the Istanbul Ve-
nereal Diseases Hospital in Turkey. To maintain subject
confidentiality, a unique identification number was assigned
to each specimen.
HIV-1 RNA detection
HIV-1 RNA was detected and quantified by a commercial
real-time PCR assay—QIAsypmhony + Rotorgene Q/artus
HIV-1 QS-RGQ v1 (Qiagen GmBH, Hilden, Germany), CO-
BAS Ampliprep/COBAS TaqMan HIV-1 Test (Roche Mole-
cular Systems, Inc., Pleasanton, CA), and Abbott M2000 SP/
Abbott RealTime HIV-1 Amplification Kit (Abbott Molecular
Inc., Des Plaines, IL).
PCR amplification and sequence analysis
A genotypic resistance test was performed by population
sequencing of the viral protease and part of the reverse tran-
scriptase (RT) using an in-house method. Specific primer pairs
were designed according to the ANRS (AIDS National Re-
search Agency) drug resistance interpretation algorithm
(www.hivfrenchresistance.org). The polymerase chain reac-
tion (PCR) condition was applied as following: RT (codons 41–
238): outer primers (798 bp); MJ3: 5¢-agtaggacctacacctgtca-3¢
(2,480 to 2,499) and MJ4: 5¢-ctgttagtgctttggttcctct-3¢ (3,399 to
3,420), inner primers (573 bp) A(35): 5¢-ttggttgcactttaaatttt
cccattagtcctatt-3¢ (2,530 to 2,558) and NE1(35): 5¢-cctactaactt
ctgtatgtcattgacagtccagct-3¢ (3,300 to 3,334). Sequencing
primer; A(20): 5¢-attttcccattagtcctatt-3¢. Protease (codons 23–
90): outer primers: 5¢ prot 1: 5¢- taattttttagggaagatctggccttcc-3¢
(2,082 to 2,109) and 3¢ prot 1: 5¢-gcaaatactggagtattgtatggatttt
cagg-3¢ (2,703 to 2,734), inner (amplification: 507-bp frag-
ment) and sequencing primers 5¢ prot 2: 5¢-tcagagcagaccaga
gccaacagcccca-3¢ (2,136 to 2,163) and 3¢ prot 2: 5¢-aatgctt
ttattttttcttctgtcaatggc-3¢ (2,621 to 2,650). HIV-1 cDNA syn-
thesis was done with the First Strand cDNA Synthesis Kit
(Thermo Scientific Inc., Fermentas, Lithuania) including the
M-MuLV reverse transcriptase enzyme. The PCR conditions
were 95C for 10 min, and then 45 cycles consisting of 95C for
45 s, 55C for 45 s, and 72C for 45 s.12
All PCR products were purified using the Highly Pure PCR
Product Purification Kit (Roche Diagnostics GmbH, Man-
nheim, Germany) and directly sequenced with ABI PRISM
310 Genetic Analyzer equipment using the DYEnamic ET
Terminator Cycle Sequencing Kit (Amersham Pharmacia
Biotech Inc., Piscataway, NJ). The following thermal protocol
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Table 1. Demographic Characteristics of the Patients Infected with HIV-1
Characteristic Study group
Patient, n 1,306
Gender, M/F (%) 1151/155 (88/12)
Age, median years (range) 36 (3–4)
CD4+ T-cell count, median mm3 (range) 361 (4–1,351)
HIV-RNA load, median IU/ml (range) 2.59 + E6 (6.8 + E2–3.29 + E6)
HIV-1 subtype, n (%) Subtype B 885 (68) — —
Non-subtype B 136 (10) A1 48 (3.6)
C 21 (1.6)
D 3 (0.2)
F 2 (0.1)
F1 24 (1.8)
F2 1 (0.07)
G 36 (2.7)
K 1 (0.07)
Circulating
recombinant
form (CRF)
285 (22) CRF01_AE 132 (10.1)
CRF 02_AG 85 (6.5)
CRF 03_AB 13 (1)
CRF 06_cpx 3 (0.2)
CRF 07_BC 1 (0.07)
CRF 08_BC 1 (0.07)
CRF 11_cpx 3 (0.2)
CRF 12_BF 33 (2.5)
CRF 13_cpx 3 (0.2)
CRF 14_BG 11 (0.8)
Sampling, region/city of Turkey Marmara/Kocaeli, _Istanbul, Edirne, Bursa, Sakarya
Black Sea/Samsun, Artvin, Giresun, Trabzon, Bolu
Southeast Anatolia/Urfa, Diyarbakir, Gaziantep
Central Anatolia/Ankara, Kayseri
Aegean/_Izmir, Denizli, Cxanakkale
Mediterranean/Antalya, Adana, Mersin
Acquisition route, n (%) Heterosexual contact 674 (52)
MSM 563 (43)
Bisexual contact 47 (3.6)
Blood transfusion 8 (0.6)
Injection drug use 4 (0.3)
Tattoo 4 (0.3)
Dental/medical surgery 2 (0.1)
Breast-feeding 2 (0.1)
Vertical route 2 (0.1)
Total 1,306 (100)
Coinfection status, n (%) Hepatitis B 35 (2.7)
Syphilis 18 (1.4)
Tuberculosis 14 (1.1)
P. jiroveci pneumonia 11 (0.8)
Hepatitis C 7 (0.5)
Kaposi sarcoma 7 (0.5)
Candida esophagitis 7 (0.5)
HPV infection 4 (0.3)
Hepatitis D 3 (0.2)
Herpes zoster 3 (0.2)
Toxoplasmosis 3 (0.2)
Condyloma 2 (0.15)
CMV retinitis 1 (<0.1)
Cryptococcal meningitis 1 (<0.1)
PML 1 (<0.1)
Total 117 (8.9)
M/F, male/female; MSM, men who have sex with men; HPV, human papilloma virus; CMV, cytomegaloviru; PML, progressive
multifocal leukoencephalopathy.
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was used for the cycle sequencing: 35 cycles consisting of
95C for 20 s, 50C for 25 s, and finally 60C for 2 min. The
sequences obtained with an electropherogram were assem-
bled using Vector NTI v.5.1 (InforMax, Invitrogen, Life
Science Software, Frederick, MD).
Drug resistance mutation detection
Drug resistance mutations were analyzed using the Stanford
HIV Drug Resistance Database (www.hivdb.stanford.edu),
and TDRMs were defined according to the mutation list pub-
lished for the surveillance of TDRMs (SDRM) as recom-
mended by the WHO. The WHO SDRM list included only
consensus nonpolymorphic drug resistance mutations at 43
positions in HIV-1 protease and RT. Selected mutations were
defined as those occurring at a prevalence £0.5% in ART-
naive individuals in subtypes for which >1,000 sequences were
available.14 However, thymidine analogue-associated muta-
tions (TAMs) were evaluated for the first time in Turkish
patients in two distinct genotypic profiles: TAM1 and TAM2,
as well as in TAM1 + TAM2 profiles.
HIV-1 subtyping
The HIV-1 subtype was determined by use of the HIVdb
Stanford University and geno2pheno (http://coreceptor.bioinf
.mpi-inf.mpg.de) subtyping tools. The information was then
compared to the consensus subtype B reference sequence, and
the differences were used as query parameters to interrogate the
HIV database as rapid computer-assisted virtual phenotyping.
The submitted nucleotide sequences were assigned Gen-
Bank accession numbers KT284379–KT285684.
Statistical analysis
Differences between two proportions were measured using
Pearson’s v2 test or Fisher’s exact test (see Supplementary data:
Fisher Exact Test; Supplementary Data are available online at
www.liebertpub.com/aid). p £ 0.05 was considered statistically
significant. Statistical analyses were performed using SPSS
for Windows statistical software (SPSS Inc., Chicago, IL).
Results
The average TDRM prevalence was detected as 10.1% (133/
1306) in newly diagnosed HIV-1-infected patients in Turkey.
The frequencies of the primary drug resistance for NRTIs,
NNRTIs, and PIs were 0.6% (8/1,306), 3.3% (44/1,306), and
2.3% (30/1,306), respectively. However, most of the NRTI
TDRMs were TAMs and were evaluated in three categories as
TAM1, TAM2, and TAM1 + TAM2 in the NRTI class (Table
2). The frequency of the TDRM for NRTI + TAMs was 8.1%
(107/1,306). K65R and M184V for the NRTI class, L100I,
K101E, K101P, K103N, K103S, V179F, Y188H, Y188L,
Y188M, Y181I, Y181C, G190A, G190E, and G190S for the
NNRTI class, and M46L, I50V, I54V, Q58E, L76V, V82A,
V82C, V82L, V82T, N83D, I84V, and L90M for the PI class
were found as primary drug resistance mutations. Some HIV-1
TDRMs were discovered for the first time in Turkish patients—
these are L100I, V179F, and Y188M for the NNRTI and I50V,
Q58E, and V82A/C for the PI drug class. However, the dif-
ferences between NRTI, NNRTI, and PI drug class resistance
prevalence were not significant (Fisher’s exact test, p ‡ 0.05). In
addition, the TDRM prevalences between the present data and
our recently unpublished (in 2014, n = 774 and sampling from
newly diagnosed, treatment-naive HIV-1-infected Turkish
patients) data were not significant (Fisher’s exact test, p ‡ 0.05).
The prevalences of the TAM1, TAM2, and TAM1 + TAM2
profiles and the particular mutations present were as follows:
7.4% (97/1306) and M41L, L210W, and T215Y for TAM1,
3.9% (52/1306) and D67N, K70R, K219E/Q/N/R, T215F, and
T215C/D/S for TAM2, and 0.7% (10/1306) and M41L +
K219N and M41L + T215C/D/S for TAM1 + TAM2 (Table 2).
Differences in the prevalence of TAM1 vs. TAM2, TAM1 vs.
TAM1 + TAM2, and TAM2 vs. TAM1 + TAM2 were sig-
nificant (Fisher’s exact test, p = 0.01, p = 0.02, and p = 0.02,
respectively).
HIV-1 subtyping results are shown in three categories. Ac-
cording to the results, subtype B was dominant, found in 68%
(885/1,306) of study patients, while non-subtype B and circu-
lating recombinant form (CRF) subtypes were found in 10%
(136/1,306) and 22% (285/1,306), respectively. The difference
in the prevalence of HIV-1 subtypes was not significant
(Fisher’s exact test, p ‡ 0.05). The non-subtype B category
included five subtypes (C, D, F, G, and K) and three
subsubtypes (A1, F1, and F2). However, seven CRF sub-
types (CRF01_AE, CRF02_AG, CRF03_AB, CRF07_BC,
CRF08_BC, CRF12_BF, and CRF14_BG) and three cpx
subtypes (CRF06_cpx, CRF11_cpx, and CRF13_cpx) were
found (Table 1).
Table 2. Primary Drug Resistance Mutations in Newly Diagnosed HIV-1-Infected
Patients in Turkey (Between 2010 and 2015, n = 1,306)
Drug class Drug resistance mutationa nb %
NRTI K65R, M184V 8 0.6
TAM1 M41L, L210W, T215Y 97 7.4
TAM2 D67N, K70R, K219E/Q/N/R, T215F, T215C/D/S 52 3.9
TAM1 + TAM2 M41L + K219N, M41L + T215C/D/S 10 0.7
107 8.1
NNRTI L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, G190A/E/S 44 3.3
PI M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, L90M 30 2.3
Total 133 10.1
aSubtype of HIV-1 is not a variable in the identification of drug resistance mutation.
bThe number of n consisted of each mutation detected patient.
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitors; PI, protease inhibitors; TAM,
thymidine analogue-associated mutation.
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Discussion
In the past few years, HIV-1 TDRMs have been analyzed all
around the world. Previous studies have found the risk of
transmitted HIV-1 drug resistance to be of 5–18% in the
United States and Europe, 13.8% in Asia, and 2.2–24% in
Africa.15–18 According to our unpublished study in 2014, the
prevalence of HIV-1 TDRMs was found to be 6.7% in 774
newly diagnosed treatment-naive Turkish patients.19 Although
new TDRMs of HIV-1 were found here, the prevalence was
higher than our previously published and/or unpublished
reports. However, the prevalence of HIV-1 TDRMs is still
moderate in Turkey. This moderate assessment of TDRM
frequency may influence the costs necessary for the analysis
and management of ART-naive Turkish patients. The low
median CD4+ T cell count in the study suggested that many of
the patients may be late presenters. This may affect the level
and TDRM type in Turkey. However, our results still show that
genotypic resistance testing must remain an integral part of the
management of HIV-1 infection in Turkey.
There are some similarities in surveillance strategies be-
tween our study and The SPREAD Programme of Europe:
both studies used a population sequencing technique, accu-
mulated surveillance data for the long term, sampled randomly
from multiple areas, and had a large patient size for newly
diagnosed HIV-1 infection. The average prevalence of TDRM
in the SPREAD Programme was 8.4% and the frequencies of
NRTI, NNRTI, and PI resistance were 4.7%, 2.3%, and 2.9%,
respectively.20 Turkey showed a higher average prevalence
than the SPREAD Programme. This higher TDRM prevalence
and the discrepancy in NRTI resistance between Turkey and
Europe may be associated with TAMs.18 Furthermore, the
surveillance periods in both studies are different. Our study
was performed in 2010–2015, but the SPREAD programme
was performed in 2002–2006. However, the backbone treat-
ment using mostly tenofovir + emtricitabine (*81%, unpub-
lished data) in Turkey and the lower circulation or decreasing
K65R and M184V mutation frequency are important for first-
line therapy in HIV-1-infected patients. The lower prevalence
of NRTI backbone treatment mutations and the higher prev-
alence of TAMs may be associated with an increase in HIV-1
infection in men who have sex with men (MSM) in the past 2
years (in 2012, 23% of patients were MSM, compared to 43%
in this study).12
Significant proportions of the patients with TDRMs have
revertant TAMs, which transmit but do not reduce drug sus-
ceptibility. The largest proportion of TAMs included first by
position of 215C/D/F/S/Y and second D67N, K219Q, or
M41L mutations.21–23 TAMs are shown in Table 2, but have
been evaluated separately in TAM1, TAM2, and TAM1 +
TAM2 genotypic profiles. Our analysis clearly shows that
TAM1 profile mutations are significantly more prevalent than
TAM2 or TAM1 + TAM2 in Turkey ( p ‡ 0.05). This may be
due to M41L, which frequently occurred as a single resistance
mutation in untreated patients.
However, according to new findings, the detection of a
single M41L mutation at baseline did not influence the de-
velopment of resistance in vitro or virological outcome on a
tenofovir-containing regimen in patients.24 In addition, codon
215 is known to be atypical or a partial revertant amino acid
position, which occurs in approximately 3% of newly diag-
nosed patients in the United States.25,26 In Turkey, the T215F
and T215C/D/S mutations were categorized in TAM2 and in
our study the proportion of TAM2 was determined to be 3.9%
(Table 2). However, there are no previous data available on the
frequency and type of TAM1 and TAM2 profiles in HIV-1-
infected patients in Turkey, and this study provides these data
for the first time.
The molecular evidence from the present study indicates
that subtype B is the most prevalent subtype among newly
diagnosed HIV-1-infected patients in Turkey. However, trends
in HIV-1 circulation in Turkey seem substantially heteroge-
neous with five non-subtype B, three non-subsubtype B, seven
CRF subtypes, and three cpx subtypes of HIV-1 in spite of the
dominance of subtype B. This heterogeneity may be associated
with demographic changes in Turkey due to its specific geo-
graphic location: an increase in the number of refugees, es-
pecially from Syria (nearly 1.7 million since the 2011 crisis)
and several countries from Africa, an increase in asylum
seekers (nearly 100,000 as of January 2015, originating mainly
from Iraq, Afghanistan, the Islamic Republic of Iran, and
Somalia), ongoing human trafficking (84% suspected to be for
sexual exploitation), and movements of tourists.27–29 Subtype
diversity of HIV-1 is a major challenge in the development of a
global control strategy for HIV-1 circulation.
In conclusion, moderate HIV-1 TDRM prevalence shows
that drug resistance testing must remain an integral part of the
management of newly diagnosed HIV-1-infected patients in
Turkey. In addition, long-term and large-scale monitoring on
regional levels of HIV-1 TDRMs informs treatment guide-
lines and provides feedback on the success of HIV-1 pre-
vention and treatment efforts.
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